OS Therapies refiles IPO for a modest $6M to fund phase 2 HER2 drug, preclinical ADCs

CAR-T Digest - August 2020

01 Aug 2024: OS Therapies refiles IPO for a modest $6M to fund phase 2 HER2 drug, preclinical ADCs

OS Therapies is listing on the NYSE American with a $6.4 million IPO to advance its immunotherapy and antibody-drug conjugate projects
The company had originally planned a $10 million IPO, but revised this to 1.6 million shares priced at $4 each
The IPO is expected to generate $6.4 million in gross proceeds, with a potential additional $960,000 if underwriters exercise their option to purchase more shares
The funds from the IPO will primarily support the clinical development of OS Therapies’ existing programs, including OST-HER2, which is in clinical trials
Initial data from a phase 2b trial of OST-HER2 in recurrent osteosarcoma showed a one-year event-free survival rate of 32.5%